CEP-11981

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCEP-11981
Drug Alias NameCEP-11981SSR-106462BOL-303213XESK-981
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTEK receptor tyrosine kinase antagonistsVascular endothelial growth factor receptor 2 antagonists
TargetsVascular endothelial growth factor receptor 2TEK receptor tyrosine kinase
Therapy Area/IndicationsBone metastasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiTeva Pharmaceutical Industries LtdUniversity Of Michigan Rogel Cancer Center
Inactive CompaniesBarbara Ann Karmanos Cancer InstituteCephalon
Active IndicationsProstatic NeoplasmsPancreatic NeoplasmsGastrointestinal Neoplasms +[6] 
Inactive IndicationsBone metastasesProstatic Neoplasms, Castration-ResistantNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A